A mid-stage hit with its ulcerative colitis project could see the company on course for blockbuster sales.
April should mark the approval of some of the biggest drugs of 2022, including Alnylam's vutrisiran, while TG will hope to be spared pain at the PI3K adcom.
Praxis and Relmada target depression as Athira and Taurx tackle Alzheimer’s.
The second quarter should bring pivotal data for Karuna and key cardiomyopathy results for Alnylam, while Ionis's eplontersen lags in amyloidosis.
Roche awaits Tigit and Serd data, Lilly takes on obesity, and Glaxo and Pfizer race in RSV.
There are long shots and then there is troriluzole. Biohaven will soon find out if it was wise to press on with the asset.
A late-stage hit with its respiratory syncytial virus jab would be a huge validation for the group’s new focus.
March Pdufa dates are set for relatlimab as well as Akebia’s vadadustat, while Amylyx’s ALS drug heads for a panel.
Will upping the dose and changing the primary endpoint pay off?